West Nile virus (WNV) is a medically important emerging arbovirus causing serious 25 neuroinfections in humans against which no approved antiviral therapy is currently available. 26
Introduction 45
West Nile virus (WNV) is an emerging representative of the genus Flavivirus 46 belonging to the family Flaviviridae. This family also includes other medically important 47 human pathogens, such as Dengue virus (DENV), Japanese encephalitis virus (JEV), yellow 48 fever virus (YFV), Zika virus (ZIKV), and tick-borne encephalitis virus (TBEV) (1) . WNV has 49 been serologically classified into the JEV antigenic complex and divided into eight genotypic 50 lineages; from a medical point of view, the strains pathogenic for humans are designated as 51 lineages 1 and 2 (2). WNV virions (50 nm diameter) are enveloped with a host cell-derived 52 lipid bilayer containing single-stranded, plus-sense genomic RNA 11 kb in length. The WNV 53 genome encodes a single polyprotein processed into three structural (capsid, premembrane 54 or membrane, and envelope) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, 55 NS4A, NS4B, and NS5) (3-6). NS5 shows RNA-dependent RNA polymerase (RdRp) activity and 56 has been reported to be an important target for antiviral development (4). 57 WNV circulates in nature within an enzootic transmission cycle between birds as 58 reservoir hosts and bird-feeding mosquitoes, primarily involving Culex spp. as principal 59 vectors of WNV (7) . WNV was originally isolated in Africa in 1937 (8), and later caused 60 outbreaks in Europe, the Middle East, and parts of Asia and Australia (9). Following its 61 introduction into the United States in 1999, WNV rapidly disseminated across North America 62 and has further spread to Mexico, South America, and the Caribbean (10,11). In humans, 63 WNV infection often remains subclinical (12,13), but 20 -40% of those infected may develop 64 WNV disease, which manifests as a febrile illness that can progress to lethal encephalitis. 65
Symptoms include cognitive dysfunction and acute flaccid paralysis (14-16). Overall, 2,002 66 cases of WNV disease in humans were reported in the United States in 2017, 67% of which 67 were classified as neuroinvasive disease (e.g., meningitis or encephalitis) and 33% as non-68 neuroinvasive infection (https://www.cdc.gov/westnile). As no vaccines or specific therapies 69 for WNV are currently approved for humans, there is an urgent need for an effective 70 approach to treatment based on specific inhibitors of WNV replication (17). 71
Nucleoside analogs represent an important group of small molecule-based inhibitors 72 that have figured prominently in the search for effective antiviral agents (18). After they 73 enter the cell, nucleoside analogs are phosphorylated by cellular kinases and incorporated 74 into viral nascent RNA chains (19, 20) . As the 3´-hydroxyl of nucleoside inhibitors is 75 conformationally constrained or sterically/electronically hindered ("non-obligate chain 76 terminators"), or completely missing ("obligate chain terminators"), such structures exert 77 the decreased potency to form a phosphodiester linkage with the incoming nucleoside 78 triphosphate during viral RNA replication, resulting in the premature termination of viral 79 nucleic acid synthesis (21). Currently, there are more than 25 approved therapeutic 80 nucleosides used for the treatment of viral infections of high medical importance, such as 81 HIV/AIDS, hepatitis B, hepatitis C, and herpes infections (22-26). Therefore, nucleoside 82 analogs represent promising tools that can be repurposed against mosquito-transmitted 83 flaviviruses, including WNV. 84
The aim of this study was to assess anti-WNV activity and cytotoxicity in a series of 85 methyl-or azido-substituted nucleosides. We have demonstrated that the 2´-C-methyl or 4´-86 azido substituents are crucial structural elements for highly efficient WNV inhibition and low 87 cytotoxicity in cell culture. One representative of 2´methylated nucleosides, 7-deaza-2´-C-88 methyladenosine (7-deaza-2´-CMA), significantly protected WNV-infected mice from disease 89 progression and mortality, even if the treatment was started 3 days post-infection (p.i.). 90
Thus, 2´-C-methylated or 4´-azidated nucleosides merit further investigation as therapeutic 91 agents for treating WNV infections and, hypothetically, infections caused by other medically 92 important flaviviruses. 93
94
Results 95
In vitro antiviral effect and cytotoxicity of the tested compounds 96
Nucleosides with a methyl substituent at the C2´position exhibited nanomolar or low-97 micromolar dose-dependent anti-WNV activity when tested on either PS or Vero cell 98 cultures ( Table 1 , Fig. 1A ,B, and Fig. 2A,B) . 7-Deaza-2´-CMA, also denoted as MK-0608, 99 exerted the strongest antiviral effect of all 2´-C-methylated nucleosides tested, characterized 100 by EC 50 values of 0.33 ± 0.08 µM and 0.15 ± 0.05 µM for Eg-101 and 13-104, respectively. 101 EC 50 values for 2´-C-methyladenosine, 2´-C-methylguanosine, and 2´-C-methylcytidine were 102 slightly higher compared to those for 7-deaza-2´-CMA, ranging from 0.78 ± 0.16 µM to 0.96 ± 103 0.06 µM for Eg-101, and 0.66 ± 0.15 µM to 1.67 ± 0.50 µM for 13-104. Similar to 104 which is used as a positive control for in vitro antiviral screens, these compounds (at a 105 concentration of 50 µM) decreased the viral titer 10 5 to 10 6 -fold compared to mock-treated 106 cells, and the in vitro antiviral effect was stable up to 5 days p.i. (Fig. 2C ). 2´-C-Methyluridine 107 was almost inactive against both WNV strains (EC 50 > 50 µM) when tested on porcine kidney 108 stable (PS) cell monolayers, and exhibited only weak inhibitory activity in Vero cells ( Fig.  109 1A,B). 2´-C-Methyl-modified nucleosides exerted low cytotoxicity in both PS and Vero cells 110 (CC 50 > 50 µM) ( Table 1 , Fig 1C) , except 2´-C-methylcytidin had a CC 50 value of ~50 µM in PS 3 111 days post-treatment, as we reported previously (27) . 112
2´-O-Methyl-or 3´-O-methyl-substituted nucleosides demonstrated no inhibitory 113
effects on WNV replication. Similarly, 3´-deoxy nucleosides were completely inactive against 114 WNV ( Fig. 1A,B ). These compounds did not cause any morphological changes and did not 115 result in decreased PS/Vero cell viability (CC 50 > 50 µM) at concentrations up to 50 µM after 116 3 days post-treatment (Table 1) . Interestingly, 7-deazaadenosine (tubercidin) and its 7-117 cyano-and 7-carbamoyl-substituted derivatives (toyocamycin and sangivamycin, 118 respectively) were highly cytotoxic at 50 µM; therefore, their anti-WNV profiles were 119 excluded from further testing ( Table 1) . 120
We evaluated four representatives of 4´-azido-modified nucleoside scaffolds for their 121 The antiviral effects of WNV inhibitors identified by viral titer/CPE inhibition assays 137 were confirmed by immunofluorescent staining, which was used to assess the expression of 138
WNV surface E antigen in PS cells as an index of viral infectivity and replication in vitro. 139
Though the surface E protein was highly expressed in WNV-infected mock-treated cells ( Fig.  140 1D), no viral antigen was detected in mock-infected cells (data not shown). 141
Immunofluorescent staining revealed that 50 μM 7-deaza-2´-CMA, 2´-C-methyladenosine, 2´-142 C-methylguanosine, 2´-C-methylcytidine, or 4´-azido-aracytidine suppressed the expression 143 of WNV surface E antigen, from both the Eg-101 and 13-104 strain, in virus-infected PS cells 144 ( Fig. 1D ). As expected, WNV surface antigen was expressed extensively in cells treated with 145 2´-C-methyluridine ( Fig. 1D ). Slight E protein expression was also observed in cells infected 146 with 13-104 strain treated with 4´-azidocytidine (data not shown). The results correlate with 147 the observed inhibition of WNV replication in compound-treated cell cultures. 148
149

Antiviral efficacy of 7-deaza-2´-CMA in a mouse model of lethal WNV infection 150
Based on 7-deaza-2´-C-methyladenosine strongly inhibiting WNV replication in vitro, 151 we used this nucleoside to demonstrate its anti-WNV effect in a mouse model of WNV 152 infection ( Fig. 3A ). WNV strain Eg101 exhibits low pathogenicity in adult mice (28); therefore, 153 WNV strain 13-104 was used in the in vivo experiments. BALB/c mice infected 154 subcutaneously with a lethal dose of strain 13-104 (10 3 PFU/mouse) exhibited characteristic 155 clinical signs of infection, such as ruffled fur, hunched posture, tremor, and paralysis of the 156 limbs within days 7 to 12 p.i., with the majority of mice requiring euthanasia (Fig. 3C ). The 157 infection was accompanied by a rapid loss of body weight starting 7 days p.i., more than 20% 158 by 12 days p.i. (Fig. 3D ). The mortality rate was 95 -100% with a mean survival time of 10.5 ± 159 1.9 days ( Fig. 2B) . Viable virus was detected in the brains of WNV-infected mice 10 days p.i., 160 which was characterized by a mean viral titer of 3.87×10 4 PFU/mL ( Fig. 3E ). 161
Treatment with 25 mg/kg of 7-deaza-2´-C-methyladenosine twice a day, initiated at 162 the time of virus inoculation and ceased 19 days p.i., resulted in a 100% survival rate 163 (P<0.0001) among WNV-infected mice ( Fig. 3B ). Nine of ten animals exhibited no clinical 164 signs during the entire 28-day monitoring period; in one mouse we observed slightly bristled 165 fur and slowing activity between 13 and 20 days p.i ( Fig. 3C ). WNV-infected 7-deaza-2´-CMA-166 treated mice had a slight loss of body weight (8.2%) by 17 days p.i.; the weight began to 167 increase again after 18 days p.i. ( In contrast, 7-deaza-2´-CMA, in which a C2´methylated riboside is bound to a 7-208 deaza-modified adenine, exhibited significantly increased anti-WNV efficacy and low 209 cytotoxicity in both cell lines. This nucleoside has been reported to have greater metabolic 210 stability, better bioavailability, and longer half-life in beagle dogs and rhesus monkeys than 211 its parent compound, 2´-C-methyladenosine (33). Moreover, 7-deaza modification 212 introduced into anti-DENV nucleoside 2´-C-ethynyladenosine resulted in a dramatic decrease 213 in compound cytotoxicity, as demonstrated in multiple cell-based systems and in vivo (51). 214
Interestingly, elimination of the C2´ methyl from 7-deaza-2´-CMA led to extremely high in 215
vitro cytotoxicity of 7-deazaadenosine (tubercidin) and its derivatives sangivamycin and 216 toyocamycin. Our anti-TBEV screens revealed that further modification of 7-deaza-2´-CMA at 217 position 6 (e.g., 6-hydroxyamino or 6-hydrazinyl), position 7 (e.g., 7-nitro, 7-phenyl, 7-fluoro, 218 7-cyano, 7-ethynyl, or 7-trifluoromethyl), or positions 6 and 7 (e.g., 6-dymethylamino-7-iodo, 219 6-cyclopropylamino-7-iodo, or 6-morpholino-7-iodo) led to a complete loss of antiviral 220 activity (unpublished results). We can conclude that 7-deaza modification of adenosine 221 combined with a 2´-C-methyl (or 2´-C-ethynyl) substituent results in higher antiviral activity, 222 decreased toxicity, and improved pharmacokinetic profile; however, 7-deaza modification 223 itself is responsible for a conspicuous increase in cytotoxicity. On the other hand, the lack of 224 antiviral activity of O2´ or O3´-methylated or 3´-deoxy-modified nucleosides could be 225 The treatment started at the time of infection, but does not correlate with potential 252 human drug use, as the therapy is usually initiated during the neurological phase of the 253 disease. Therefore, we tested the therapeutic effect of treatment initiated at various times 254 after WNV infection. Mice infected with WNV have peak viremia between 48 and 72 hours 255 p.i. The virus then crosses the blood-brain barrier and establishes brain infection (53,54). 256 Therefore, treatment was started in mice before viremia (1 day p.i.), during peak viremia (3 257 days p.i.), and at the time of established brain infection (8 days p.i.). Delayed start of 258 treatment (25 mg/kg, twice daily) 1 day p.i. resulted in the survival of all infected mice. Even 259 the treatment initiated 3 days p.i. (at the time of a peak of viremia) showed a had high 260 antiviral efficacy, protecting 90% of mice from disease development and mortality. However, 261 animals treated after 8 days p.i. (i.e., at the time of extensive brain infection) had only a 262 slightly higher survival rate and negligibly prolonged mean survival time compared to mock-263 treated mice. The results suggest that treatment with 7-deaza-2´-CMA is highly effective, 264 even when started 1 or 3 days p.i. (i.e., before the virus infects the brain). 
Antiviral assays 321
In order to perform the viral titer reduction assay, PS cells were seeded in 96-well 322 plates (approximately 3 x 10 4 cells per well) and incubated for 24 hours at 37°C to form a 323 confluent monolayer. The medium was then aspirated from the wells and replaced with 200 324 µl of fresh medium containing 50 µM of the test compounds and appropriate virus strain at a 325 multiplicity of infection (MOI) of 0.1. Virus-infected cells treated with BCX-4430 (63) and 326 DMSO (mock-treated cells) were used as positive and negative controls, respectively. The 327 culture medium was collected 3 days p.i. and viral titers (expressed as PFU/mL) determined 328 from the collected culture medium by plaque assays (38,64). 329
As the antiviral effect of many compounds is cell-type dependent, we further tested 330 the anti-WNV activity of nucleoside analogs in Vero cells in cytopathic effect (CPE) inhibition 331 assays. Vero cells were seeded in 96-well plates, incubated to form a confluent monolayer, 332
and treated with virus and tested compounds as described for the viral titer inhibition assay. 333
The cells were examined microscopically for virus-induced CPE. Three days p.i., the 334 supernatant medium was aspirated from the cells and the cell culture stained with 335 naphtalene black. The rate of CPE was expressed in terms of cell viability as the absorbance 
